[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Insulin Market Outlook 2018

March 2014 | 55 pages | ID: G39F7896FEEEN
RNCOS E-Services Pvt. Ltd.

US$ 1,200.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
About 381 Million people suffered from diabetes in 2013 globally, which is likely to reach 591 Million by 2035. The growing number of diabetes patients at such a high pace significantly increases the demand for insulin products. The discovery of Insulin therapy has remained as a standard treatment for both Type I diabetes. Owing to the growing prevalence of diabetes and progressive nature of the disease, the global insulin market is forecasted to grow at a CAGR of over 10% during 2012-2018.

Our RNCOS research report, “Global Insulin Market Outlook 2018”, has revealed that the Insulin market has witnessed huge growth prospects based on these novel insulin delivery device systems. Recent advancements in administration of insulin include inhalable insulin, topical patches, spray insulin and painless insulin pens/pumps. Our comprehensive research work also studies how patent expiry of block buster insulin products would create opportunities for biosimilars.

The report conducts an in-depth analysis of diabetic patient population across leading geographies including India, China, US, Russia, etc. to understand the structure of the insulin market in these countries. The report covers insulin market break up by mode of action and synthesis. Our extensive study looks into the competitive landscape key players in the insulin market covering business overview, product portfolio, market share and company level activities. Overall, the research aims at presenting a balanced picture of the global insulin market to the clients.
1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. GLOBAL PROTEIN THERAPEUTICS MARKET

3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2018
  3.2.1 Market Segmentation

4. INSULIN MARKET FORECAST TO 2018

4.1 Scientific Insight
4.2 Current and Future Market Analysis to 2018
4.3 Key Players and Drugs
4.4 By Type of Insulin
  4.4.1 Mode of Action
  4.4.2 Mode of Synthesis
4.5 By Application
  4.5.1 Regional Analysis
4.6 Key Geographical Markets
  4.6.1 India
  4.6.2 China
  4.6.3 US
  4.6.4 Russia
  4.6.5 Japan
  4.6.6 Brazil

5. PATENT EXPIRY STATUS OF INSULIN

6. KEY PLAYERS

6.1 Sanofi-Aventis
6.2 Novo Nordisk
6.3 Eli Lilly & Company
6.4 Wockhardt
6.5 Biocon

LIST OF FIGURES:

Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2013
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2013-2018
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2013
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2018
Figure 4-1: Global - Insulin Market (Billion US$), 2013-2018
Figure 4-2: Global - Share of Key Players in Insulin Market (2013)
Figure 4-3: Global - Share of Products in Insulin Market (2013)
Figure 4-4: Insulin Market by Mode of Action (%), 2013
Figure 4-5: Insulin Market by Mode of Action (%), 2018
Figure 4-6: Insulin Market by Mode of Synthesis (%), 2013
Figure 4-7: Insulin Market by Mode of Synthesis (%), 2018
Figure 4-8: Global - Number of Diabetic Patients (Million), 2013 & 2035
Figure 4-9: Diabetes Prevalence by Region (%), 2013
Figure 4-10: Diabetes Prevalence by Region (%), 2035
Figure 4-11: India - Insulin Market (Million US$), 2013-2018
Figure 4-12: China - Insulin Market (Billion US$), 2013-2018
Figure 4-13: US - Insulin Market (Billion US$), 2013-2018
Figure 4-14: Russia - Insulin Market (Million US$), 2013-2018
Figure 4-15: Japan - Insulin Market (Billion US$), 2013-2018
Figure 4-16: Brazil - Insulin Market (Million US$), 2013-2018

LIST OF TABLES:

Table 4-1: Key Insulin Product Sales (Billion US$), 2010-2013
Table 4-2: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2013 & 2035
Table 4-3: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-4: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-5: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-6: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-7: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 5-1: Global - Patent Expiry Status of Key Insulin Products
Table 6-1: Sanofi-Aventis - Insulin Products
Table 6-2: Novo Nordisk - Insulin Products
Table 6-3: Eli Lilly - Insulin Products
Table 6-4: Wockhardt - Insulin Products
Table 6-5: Biocon - Insulin Products


More Publications